Table 1 Baseline patient-, donor- and transplant-related characteristics at first- and second alloSCT.
From: How risky is a second allogeneic stem cell transplantation?
N = 3356 | First alloSCT | Second alloSCT |
|---|---|---|
Age at transplant, yrs | ||
Median [Q1, Q3] | 45.4 (31.9, 55.7) | 48.2 (34.7, 58.7) |
[Min, Max] | 2.9–77.1 | 18.1–78.4 |
Age at diagnosis, yrs | ||
Median [Q1, Q3] | 44.4 (30.9, 54.5) | |
[Min, Max] | 1.8–77.3 | |
Missing count | 3 | |
Transplant year | ||
Median [Q1, Q3] | 2014 (2011, 2017) | 2016 (2014, 2019) |
[Min, Max] | 1986–2021 | 2011–2021 |
Patient sex at birth | ||
Male | 1933 (57.6%) | |
Female | 1423 (42.4%) | |
Cell source | ||
Peripheral blood | 2778 (82.9%) | 3083 (91.9%) |
Bone marrow | 507 (15.1%) | 271 (8.1%) |
Cord blood | 60 (1.8%) | |
Peripheral blood and cord blood | 7 (0.2%) | |
Bone marrow and cord blood | 1 (0.03%) | |
Missing count | 3 | 2 |
Type of donor | ||
Identical sibling | 1295 (38.6%) | 593 (17.7%) |
Matched unrelated 10/10 | 1025 (30.6%) | 1188 (35.4%) |
Mismatched unrelated 9/10 | 295 (8.8%) | 309 (9.2%) |
Unrelated (missing data on HLA) | 701 (20.9%) | 470 (14.0%) |
Mismatched unrelated ≤8/10 | 34 (1.0%) | 46 (1.4%) |
Haploidentical HSCT | 192 (5.7%) | 750 (22.3%) |
Missing count | 3 | 0 |
Same donor as 1st alloSCT | ||
No | 2321 (79.8%) | |
Yes | 588 (20.2%) | |
Missing count | 447 | |
Karnofsky | ||
<90 | 624 (20.4%) | 1258 (40.4%) |
≥90 | 2442 (79.6%) | 1854 (59.6%) |
Missing count | 290 | 244 |
Disease relapse index | ||
Low | 881 (26.3%) | 178 (5.3%) |
Int | 2096 (62.7%) | 1247 (37.2%) |
High | 227 (6.8%) | 1562 (46.5%) |
Very high | 141 (4.2%) | 369 (11.0%) |
Hematological malignancies | ||
Acute myeloid leukemia | 2011 (59.9%) | |
Acute lymphoblastic leukemia | 502 (15.0%) | |
Myelodysplastic syndrome (MDS) | 264 (7.9%) | |
Myeloproliferative neoplasm (MPN) | 179 (5.3%) | |
Chronic myeloid leukemia | 82 (2.4%) | |
MDS & MPN | 81 (2.4%) | |
Non-Hodgkins lymphoma | 66 (2.0%) | |
Hodgkins lymphoma | 59 (1.8%) | |
Multiple myeloma | 57 (1.7%) | |
Chronic lymphatic leukemia | 55 (1.6%) | |
Myeloablative conditioning | ||
No | 1207 (36.4%) | 1828 (56.1%) |
Yes | 2110 (63.6%) | 1432 (43.9%) |
Missing count | 39 | 96 |
Total body irradiation | ||
No | 2446 (73.0%) | 2543 (76.6%) |
Yes | 905 (27.0%) | 778 (23.4%) |
Missing count | 5 | 35 |
GVHD prevention regimen | ||
Cyclosporine A + MMF based | 1457 (45.0%) | 1223 (38.7%) |
Cyclosporine A + MTX based | 936 (28.9%) | 705 (22.3%) |
Cyclosporine A based | 393 (12.1%) | 383 (12.1%) |
Tacrolimus/Sirolimus + MMF based | 242 (7.5%) | 538 (17.0%) |
Tacrolimus/Sirolimus + MTX based | 48 (1.5%) | 44 (1.4%) |
Tacrolimus/Sirolimus based | 58 (1.8%) | 99 (3.1%) |
Other | 103 (3.2%) | 168 (5.3%) |
Missing count | 119 | 196 |
In vivo T cell depletion for second alloSCT | ||
No | 1560 (48.6%) | |
Campath | 142 (4.4%) | |
ATG | 1506 (46.9%) | |
Donor to patient CMV positivity | ||
Positive to positive | 893 (28.1%) | 1395 (43.3%) |
Positive to negative | 653 (20.5%) | 286 (8.9%) |
Negative to positive | 332 (10.4%) | 766 (23.8%) |
Negative to negative | 1304 (41.0%) | 772 (24.0%) |
Missing count | 174 | 137 |
